Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE GERVASI

Allopathic & Osteopathic Physicians Urology

NPI
1265400592
CMS profile
328763
Location
MIDDLEBURG HEIGHTS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$177,656.74

249 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE GERVASI

NPI 1265400592 · CMS profile ID 328763

Allopathic & Osteopathic Physicians / Urology

MIDDLEBURG HEIGHTS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265400592?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE GERVASI, NPI 1265400592, CMS profile ID 328763. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265400592?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LAWRENCE GERVASI, NPI 1265400592, CMS profile ID 328763. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265400592?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LAWRENCE GERVASI, NPI 1265400592, CMS profile ID 328763, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1265400592?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

249 matching records · $177,656.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 249 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 249.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sun Pharmaceutical Industries Inc. $20.2408/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053902949 CMS
Blue Earth Diagnostics Limited $12.3207/31/2023 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1059982527 CMS
Janssen Biotech, Inc. $149.3507/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988311315 CMS
PFIZER INC. $20.4007/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049905147 CMS
Amgen Inc. $14.4707/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019998471 CMS
Bayer Healthcare Pharmaceuticals Inc. $364.9607/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000928678 CMS
Astellas Pharma US Inc $20.0107/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034320311 CMS
Bayer Healthcare Pharmaceuticals Inc. $152.6607/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000926629 CMS
Blue Earth Diagnostics Limited $15.2207/20/2023 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1059982523 CMS
Bayer Healthcare Pharmaceuticals Inc. $5,060.0007/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000933155 CMS
Astellas Pharma US Inc $489.1807/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034285039 CMS
Astellas Pharma US Inc $4,870.0007/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034285047 CMS
Astellas Pharma US Inc $443.4707/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034285055 CMS
Astellas Pharma US Inc $377.7307/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034285187 CMS
Astellas Pharma US Inc $17.4907/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034285269 CMS
Janssen Biotech, Inc. $13.2907/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988311333 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.9507/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000853307 CMS
Progenics Pharmaceuticals, Inc. $14.5407/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991106235 CMS
Bayer Healthcare Pharmaceuticals Inc. $470.7206/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000929529 CMS
Astellas Pharma US Inc $4,870.0006/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034235631 CMS
Astellas Pharma US Inc $440.7606/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034235639 CMS
Astellas Pharma US Inc $529.8106/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034235783 CMS
Astellas Pharma US Inc $243.2706/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034238759 CMS
Tolmar, Inc. $13.6906/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056932773 CMS
Tolmar, Inc. $3.0906/27/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056942199 CMS
Tolmar, Inc. $0.9506/27/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056959867 CMS
Verity Pharmaceuticals Inc. $16.9106/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019430005 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.9606/22/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000877515 CMS
Bayer Healthcare Pharmaceuticals Inc. $3,036.0006/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000932399 CMS
ABBVIE INC. $17.5206/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335471 CMS
Bayer Healthcare Pharmaceuticals Inc. $81.2506/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000921557 CMS
Bayer Healthcare Pharmaceuticals Inc. $102.8106/21/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000922603 CMS
Bayer Healthcare Pharmaceuticals Inc. $5,060.0006/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000933199 CMS
AstraZeneca Pharmaceuticals LP $20.3906/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011576699 CMS
Bayer Healthcare Pharmaceuticals Inc. $623.4306/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000930097 CMS
ACCORD HEALTHCARE, INC. $24.3006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052307609 CMS
Bayer Healthcare Pharmaceuticals Inc. $223.3406/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000927535 CMS
Janssen Biotech, Inc. $13.0006/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988311507 CMS
Axonics, Inc. $13.9006/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051800409 CMS
PROCEPT BioRobotics Corporation $121.7506/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057605927 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.7506/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000852027 CMS
PFIZER INC. $16.6705/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049240661 CMS
Blue Earth Diagnostics Limited $16.7805/17/2023 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1059982505 CMS
Bayer Healthcare Pharmaceuticals Inc. $410.4005/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000928853 CMS
Foundation Medicine, Inc. $13.5805/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058789057 CMS
Dendreon Pharmaceuticals LLC $1,350.0005/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060284957 CMS
Astellas Pharma US Inc $14.8205/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034100927 CMS
Astellas Pharma US Inc $38.0005/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034097079 CMS
Astellas Pharma US Inc $703.4905/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034097091 CMS
Astellas Pharma US Inc $4,175.0005/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034097189 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $198,015.38 281
PY2020 $91,147.75 149
PY2021 $104,760.68 177
PY2022 $182,488.44 241
PY2023 $177,656.74 249
PY2024 $152,151.65 224
PY2025 $145,937.60 210

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $97,228.40 28
PY2024 Principal investigator $380,223.92 43
PY2023 Principal investigator $426,904.31 37
PY2022 Principal investigator $637,507.29 81
PY2021 Principal investigator $582,019.29 97
PY2020 Principal investigator $765,957.29 159
PY2019 Principal investigator $791,586.46 139

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $27,750.00 12/23/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) No dispute reported 06/30/2026 1175427662
Principal investigator 1 Janssen Research & Development, LLC $787.50 11/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) No dispute reported 06/30/2026 1175427565
Principal investigator 1 Janssen Research & Development, LLC $26,000.00 10/30/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) No dispute reported 06/30/2026 1175427732
Principal investigator 1 Janssen Research & Development, LLC $7,311.20 06/12/2025 Non-covered Recipient Entity
Clnc Rsrch Solutions, Llc
A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1175300954
Principal investigator 1 MEDIVATION LLC. $697.45 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829382
Principal investigator 1 MEDIVATION LLC. $1,245.40 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829470
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829491
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829499
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829734
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829788
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829827
Principal investigator 1 MEDIVATION LLC. $1,406.60 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829832
Principal investigator 1 MEDIVATION LLC. $1,573.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829837
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829845
Principal investigator 1 MEDIVATION LLC. $1,406.60 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829850
Principal investigator 1 MEDIVATION LLC. $1,406.60 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829894
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829964
Principal investigator 1 MEDIVATION LLC. $1,406.60 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829972
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829978
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,500.00 04/04/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER, PA
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185537307
Principal investigator 1 MEDIVATION LLC. $1,070.00 03/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SOLUTIONS LLC
PROSPER A MULTINATIONAL PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228831590
Principal investigator 1 Sumitomo Pharma America, Inc. $6,500.00 03/05/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH INC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630235
Principal investigator 1 Sumitomo Pharma America, Inc. $5,000.00 03/05/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH INC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630239
Principal investigator 1 Sumitomo Pharma America, Inc. $1,500.00 03/05/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH INC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630242
Principal investigator 1 MEDIVATION LLC. $312.00 03/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SOLUTIONS LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228832073
Principal investigator 1 MEDIVATION LLC. $697.45 03/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SOLUTIONS LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228832250
Principal investigator 1 MEDIVATION LLC. $312.00 03/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SOLUTIONS LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228832255
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,850.00 02/05/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185537305